Table 4.

Patents protecting new antibody concepts that can be used in ADCs

Technology	Embodiment	Example IP right	Assignee	Claim language
New antibody format	Diabody	EP2516462B1	Avipep	An isolated protein comprising an immunoglobulin variable region comprising:(i) at least 2 cysteine residues positioned within framework region (FR) 2, wherein if at least 2 of the cysteine residues in FR2 are not conjugated to a compound then a disulfide bond is capable of forming between the cysteine residues in FR2; and/or(ii) at least 2 cysteine residues positioned within framework region (FR) 3, wherein if at least 2 of the cysteine residues in FR3 are not conjugated to a compound then a disulfide bond is capable of forming between the cysteine residues in FR3.
Conditionally active Biologics	Antibodies are activated and/or inactivated at defined physiological conditions.	US8709755	BioAtla	A method of preparing a conditionally active antibody, the method comprising the steps of:i. selecting a wild-type antibody against an antigen;ii. evolving the DNA which encodes the wild-type antibody using one or more evolutionary techniques to create mutant DNAs;iii. expressing the mutant DNAs to obtain at least one mutant antibody;iv. subjecting the at least one mutant antibody and the wild-type antibody to an assay under a normal physiological condition selected from the group consisting of temperature, pH, osmotic pressure, osmolality, oxidation and electrolyte concentration, and to an assay under an aberrant condition selected from the group consisting of temperature, pH, osmotic pressure, osmolality, oxidation and electrolyte concentration; andv. selecting the conditionally active antibody from the at least one mutant antibody […]
Cleavable masking peptides	Masking peptides are released, e.g., by proteases secreted by the tumor	US20100189651	CytomX	A modified antibody comprising: an antibody or antibody fragment (AB), capable of specifically binding its target, coupled to a masking moiety (MM), wherein the coupling of the MM reduces the ability of the AB to bind its target such that that the dissociation constant (Kd) of the AB when coupled to the MM toward the target is at least 100 times greater than the Kd of the AB when not coupled to the MM toward the target
Target which does not require toxin internalization	Extra domains A and B of fibronectin	US20150030536	Philogen	A method of treating lung cancer or lymphoma in an individual, comprising administering to the individual a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, which binds Extra Domain-A (ED-A) of fibronectin comprising a VH domain and a VL domain with given CDR sequences and wherein the antibody is conjugated to a molecule that has biocidal or cytotoxic activity or is conjugated to a radioisotope.

the symbol […] indicates that claim language has been truncated.